Loading
Ripretinib was not better than sunitinib as second-line treatment for gastrointestinal stromal tumour overall, but it was better tolerated and worked better in tumours with KIT exon 11 plus exon 17/18 secondary mutations, while sunitinib was better for exon 13/14 mutations.
Phase 3 open-label trial of 453 patients with advanced GIST after imatinib randomised to ripretinib or sunitinib.
Median progression-free survival was 8.3 versus 7.0 months in the intention-to-treat population (hazard ratio 0.91, not superior); ripretinib had fewer grade 3 to 4 adverse events (41 versus 66 percent) and better quality of life. Circulating tumour DNA analysis showed ripretinib superior in exon 11 plus 17/18 mutations and sunitinib superior in exon 11 plus 13/14 mutations.
Sunitinib remains the standard second-line treatment, with ripretinib as a better-tolerated alternative, and mutation-guided choice by circulating tumour DNA is being tested prospectively in INSIGHT.
Shares Imatinib-resistant GIST, Sunitinib, Imatinib.
Shares Ripretinib, Imatinib-resistant GIST, Sunitinib.
Shares Imatinib-resistant GIST, Sunitinib, Imatinib.
Shares Ripretinib, Imatinib-resistant GIST.
Shares Ripretinib, Imatinib-resistant GIST.
Shares Imatinib, Journal of Clinical Oncology.
Shares Ripretinib, Imatinib-resistant GIST.
Shares Imatinib, Journal of Clinical Oncology.